HLA Typing Market is anticipated to grow at a CAGR of 5.6% from 2020 to 2030.
Market Industry Reports (MIR) has published a new report titled “HLA Typing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030.” According to the report, the global HLA typing market accounted for over US$ 1.1billion in 2019. It is anticipated to grow at a CAGR of 5.6% from 2020 to 2030.
The increasing incidents of infectious and non-infectious diseases worldwide can be attributed to growth of the HLA typing market. In the current scenario, organ transplants are being widely performed to treat several diseases such as renal failure, cardiovascular diseases, and others. HLA typing is performed to checking donor-recipient organ compatibility, further ensuring safety for organ transplants. Hence, carrying out HLA typing is one of the crucial steps to be taken prior to transplantation surgeries, in turn, promoting market growth. Moreover, increasing research for the development of treatments for autoimmune diseases, such as rheumatoid arthritis, celiac disease, Systemic Lupus Erythematosus (SLE), myasthenia gravis, etc., is promoting market growth. However, the high costs associated with HLA typing and organ transplantation are hindering market growth.
Owing to the changes in disease patterns across the world, a significant increase in non- communicable diseases, such as cardiovascular diseases (CVDs), cancers, kidney diseases, and diabetes mellitus, has been observed. Organ transplantation is capable of combating the rising prevalence of such diseases. For instance, in 2018, according to the Canadian Organ Replacement Register (CORR), a total of 2,782 organ transplant procedures were performed in Canada. The rate of transplantation had increased by 33% as compared to 2009. Hence, the increasing cases of organ transplantation for treating several non- communicable diseases boosted growth of the HLA typing market.
There are several government initiatives that promote organ transplantation, in turn, contributing to growth of the HLA typing market. For instance, in 2019, new policies were launched to strengthening American Kidney Health. These new policies promote affordable alternative treatments for chronic kidney disease and End-Stage Renal Disease (ESRD) by encouraging kidney transplants. In addition, an awareness initiative was launched by the Department of Health and Human Services to educate patients regarding the prevention and treatment options for kidney-related diseases. Similarly, in 2019, the U.S. Department of Health and Human Services (HHS) increased the availability of organs for around 113,000 Americans who were waiting for lifesaving organ transplants. To ensure safe organ transplantation, HLA typing is performed, which promotes growth of the HLA typing market.
Browse key industry insights spread across 160 pages with market data tables & figures & charts from the report, HLA Typing Market by Product & Services (Reagents & Consumables, Instruments, and Software & Services), Technology (Molecular Assay Technologies and Non-Molecular Assay Technologies),Application(Diagnostic Applications and Research Applications), End User (Commercial Service Providers, Hospitals & Surgical Centers, and Research Laboratories & Academic Institutes)- Global Analysis & Forecast 2020-2030 in detail along with the table of contents:https://www.marketindustryreports.com/hla-typing-market/285
Despite the increase in organ donations from both deceased and living donors, the inadequate financial coverage for organ transplantation remains a major concern. Hence, the high cost of transplants and post-transplant immunosuppression therapy limits people opting for transplantation, which will hinder growth of the HLA typing market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period. Increasing incidents of non-communicable diseases, improving healthcare facilities, rising R&D; activities, and government initiatives will boost growth of the HLA typing market in these regions.
Some of the prominent players operating in the global HLA typing market are Thermo Fisher Scientific Inc., Illumina, Inc.,QIAGEN, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Immucor, Biofortuna Limited, GenDx, CareDx Inc., and R.O.S.E. GenTec Ltd., among others.
Market Industry Reports (MIR) believes in sharing accurate market-related insights. The information that we obtain is from authentic sources and key opinion leaders in the industry. We take efforts to ensure that the information published by us is both reliable and accurate; however, we take no liabilities for any inaccuracy in the information obtained from users, manufacturers, or other sources; opinion, projections, and estimates may be subject to fluctuations and changes.
This report is intended for internal use by the customer and not for disclosure to third parties or general publications. No part of the report or the report as a whole may be reproduced, resold, lent, circulated or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without explicit permission from MIR. Neither MIR nor any of our partner companies take responsibility for any short-term or long-term decisions taken by our clients based on insights present in our publications.